NCT00406640

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women

A Multicenter, Randomized, 8-Week Double-Blind Acute Phase Followed By a 6-Month Continuation Phase (Open-Label Or Double-Blind) Study to Evaluate the Efficacy, Safety, and Tolerability of DVS SR Versus Escitalopram in Postmenopausal Women With Major Depressive Disorder

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 595 (actual)
• Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer · Industry
• Sex: Female
• Age: 40 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). This study will investigate the safety, efficacy, and tolerability of DVS SR versus escitalopram in women with major depressive disorder (MDD) who are postmenopausal.

Conditions

• Depression
• Depressive Disorder
• Depressive Disorder, Major

Interventions

Type	Name	Description
DRUG	Desvenlafaxine succinate sustained-release (DVS SR)	flexible dose of DVS 50-100 or 200 mg every day during 56 days. Extension until 6 months.
DRUG	Escitalopram	Flexible dose of Escitalopram 10 or 20 mg every day during 56 days. Extension until 6 months.

Timeline

• Start date: 2006-12-01
• Primary completion: 2008-02-01
• Completion: 2008-10-01
• First posted: 2006-12-04
• Last updated: 2023-12-28
• Results posted: 2010-06-29

Locations

70 sites across 6 countries: United States, Argentina, Chile, Colombia, Mexico, Peru